What are the opening hours?

Monday 10am - 6pm Tuesday 7am - 5pm Wednesday 7am - 5pm Thursday 2pm - 10pm Friday 2pm - 10pm Saturday 10am - 5pm Sunday 6pm - 10pm

http://Researcher.O.G/, https://GlobalCannabinoidRC.com/, https://GenevievesDream.com/

The Researcher OG, Santa Barbara, CA (2026)

09/06/2026

There are three major cannabinoid directions people need to understand when they talk about this plant: THC, C*D, and CBG. Each has its own type of cannabis expression, chemistry, and role in the larger conversation.

The problem is that media, research, healthcare, and even the cannabis industry often say “cannabis” without telling people what type of cannabis they’re actually talking about.

That matters because a THC-dominant plant is not the same as a C*D-dominant h**p plant, and a CBG-dominant plant is another conversation altogether.

In the science, these are often described as chemotypes.

Type I is generally THC-dominant, Type II is mixed THC/C*D, Type III is C*D-dominant, and Type IV is CBG-dominant, where CBGA can accumulate because the plant’s chemistry isn’t pushing as heavily into THCA or C*DA production.

Research on cannabis chemotypes has made this clear, and newer genomic work continues to show that cannabinoid expression is driven by the plant’s synthase genes and chemotype-determining loci.

This is why I push back when people make broad claims about cannabis without naming the plant type.

A THC flower study does not automatically explain C*D h**p. A C*D product study does not automatically explain CBG. A CBG-dominant plant does not behave like a high-THC plant just because they’re both Cannabis sativa L.

The plant family is shared, but the chemistry can differ greatly.

Patients deserve better language. Growers deserve better language. Researchers definitely need better language. When we say cannabis, we should be asking what kind, what chemotype, what cannabinoid profile, what terpene profile, what ratio, what route, and what person is using it.

THC, C*D, and CBG are not just product labels. They represent different major lanes of the plant, and each lane can lead to a different experience, different therapeutic potential, and different ECS response.

Cannabis isn’t one thing; it’s a library. If we don’t name the book we’re reading, we can’t teach the lesson right.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

Cannabis Inflorescence for Medical Purposes: USP Considerations for Quality Attributes
https://pubmed.ncbi.nlm.nih.gov/32281793/
The Structure of the Chemotype Determining Locus in Cannabis sativa
https://pmc.ncbi.nlm.nih.gov/articles/PMC13128303/
Identification of a New Chemotype in Cannabis sativa: Cannabigerol-Dominant Plants
https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-2006-962705

09/06/2026

A September 2026 human study looked at C*D, alcohol use disorder, and brain responses during threat anticipation. The study used a randomized, double-blind, placebo-controlled crossover design in people diagnosed with AUD, giving 800 mg/day of C*D or placebo before fMRI testing.

The target was important: C*D has been studied for AUD, stress biology, anxiety, craving, and endocannabinoid signaling, but the mechanisms are still mixed. Researchers tested whether C*D changed cognition, anxiety, craving, or brain activation during high-threat versus low-threat anticipation.

The result was cautious. Sixteen participants had complete behavioral data, fourteen had usable fMRI data, and C*D did not produce measurable effects on cognition, regional brain activation, whole-brain activation, anxiety, or craving during threat anticipation.

Drinking the day before the scan was linked with slower task responses, and craving increased during the scan, but C*D itself didn’t change the main outcomes.

This doesn’t erase C*D’s potential in AUD research. The authors suggest C*D effects may be stronger during direct emotional or alcohol-cue processing than during anticipation alone.

For me, that’s the lesson: cannabinoid medicine needs the right patient, signal, timing, dose, and outcome measure.

This is Possible With Caveats- good human design, small sample, neutral main result, and valuable for keeping C*D claims honest.

C*D research in alcohol use disorder shows why we need clean human trials - the cannabinoid, the brain signal, and the timing of the test all shape the outcome.

-Mike Robinson, Global Cannabinoid Research Center
"Cannabidiol and neural correlates of threat anticipation in alcohol use disorder" - September 2026 https://link.springer.com/article/10.1007/s00213-026-07148-y

09/05/2026

This is cannabis under a scanning electron microscope, and even without the plant’s natural color, it’s still one of the most beautiful things we can study. What you’re looking at are capitate glandular trichomes, the mushroom-shaped resin heads that hold so much of the chemistry people associate with this plant.

Each one sits on a delicate stalk with a glandular head covered by a thin cuticle, and underneath that covering, specialized cells produce and store the secondary metabolites that eventually become part of the plant’s medicine, aroma, flavor, and identity.

Those long pointed structures around them are different. They’re protective hairs, not the same resin-producing glands, and they remind us that cannabis has multiple surface structures doing different jobs at the same time. Some protect the plant, some store resin, some develop later, some mature earlier, and all of them are shaped by genetics, where they sit on the plant, how old the flower is, and how the plant was grown.

A scanning electron microscope doesn’t use ordinary light like a camera. It uses a focused beam of electrons to read the surface and reveal detail most of us would never see with the naked eye. The colors are added later to help separate structures visually, so they don’t tell us potency, terpene profile, maturity, microbial status, or cannabinoid content. For that, we still need proper sampling, microscopy, and analytical chemistry.

This image also teaches something every grower, processor, and patient should understand. Trichome heads are exposed, fragile, and easy to damage. Rough handling, mechanical trimming, drying mistakes, too much movement, and repeated contact can break, collapse, or knock them loose. What looks minor to us can be real damage at this scale.
Cannabis is beautiful from across the room, but under the microscope, the plant shows us why respect matters. The medicine is powerful, but it’s also delicate.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

09/05/2026

Just released in August 2026, a new comprehensive review maps how natural and synthetic cannabinoids may affect cancer-cell survival in laboratory models. For many of us Cancer Survivors, watching the slow rollout of research is frustrating; we already know what the plant can do.

Back to the science, the review "Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities" focuses on regulated cell death pathways, including apoptosis, autophagy-dependent cell death, necroptosis, ferroptosis, and parthanatos.

Researchers have not yet shown that cannabinoids are proven cancer treatments. But they have shown that the mechanisms are serious: tumor growth, angiogenesis, metastasis, oxidative stress, ceramide signaling, PI3K/AKT/mTOR, MAPK/ERK, NF-kB, JNK, p38-MAPK, and other pathways all appear in the cannabinoid cancer research map.

The review also notes that cannabinoids may sometimes enhance conventional anticancer therapy through complementary cell-death pathways.

Most evidence remains preclinical, with major gaps in safety, dosing, formulation, and clinical efficacy. Established use is still strongest in palliative care areas like chemotherapy-induced nausea, cachexia, mood, and sleep support.

The caveats in research for cannabinoids seem to be in understanding mechanisms; these are growing, but not strong enough for claims that THC, C*D, CBG, or other cannabinoids treat cancer.

Despite the mountain of millions of people who have used cannabinoids during a cancer battle, the proof for most scientific researchers must be in the petri dish before it can move to a working trial that includes patients.

Cannabinoid cancer research is moving far more into cell-death pathways, oxidative stress, and tumor signaling, and more. It's positive and hopeful, despite all of us who've beaten cancer - our victory is not the same as clinical proof.

It's nice to see research slowly catch up to what the Cannabis Community has known for decades - the plant we love, the one the government minimizes until it wants profit - gets our personal credit for helping us live through a Cancer battle.

-Mike Robinson, Global Cannabinoid Research Center

"Cannabinoids in Cancer: Molecular Mechanisms of Tumor Cell Death and Translational Opportunities" - August 2026 https://www.mdpi.com/2218-273X/16/9/1260

09/05/2026

I’ve watched children with developmental delays go through what I can only describe as an awakening of sorts when cannabinoid medicine finally begins working with their system.

It’s one of the most remarkable things I’ve ever seen in this world of plant medicine, especially when a child who seemed distant, shut down, overloaded, or locked behind a blank expression suddenly starts showing emotion, laughter, eye contact, curiosity, comfort, and presence.

That doesn’t mean cannabinoids “fix” a child, because that’s not how I see these kids at all. They’re not broken. Many are overwhelmed, inflamed, sensory overloaded, anxious, sleepless, gut-disrupted, seizure-prone, or struggling with communication systems that most people don’t understand.

When the ECS gets support, some children seem to find more room inside their own nervous system to connect with the world around them.

The science is catching up to what families have reported for years. Research has shown that children with autism spectrum disorder can have lower circulating endocannabinoid levels, including anandamide, PEA, and OEA, and another study found plasma anandamide concentrations were lower in autistic children.

That matters because endocannabinoids help guide synaptic signaling, social reward, stress response, sensory processing, gut-brain communication, sleep, inflammation, and emotional regulation.

Clinical research is moving too. Studies of C*D-rich cannabis in autistic children have reported improvements in areas such as social interaction, anxiety, sleep, agitation, and some behavioral measures. At the same time, newer randomized trials remind us that responses vary and more research is still needed.

This is why I speak carefully, but I also speak from what I’ve witnessed. I’ve seen blank expressions soften into laughter. I’ve seen children come back to the present and start learning again. I’ve seen parents cry because they finally saw a piece of their child reach through.

Cannabinoids don’t replace love, therapy, nutrition, sleep, medical care, or patience, but for some children, they may help the ECS create enough calm for connection.

That awakening is real to the families who see it.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

Lower circulating endocannabinoid levels in children with autism spectrum disorder
https://pmc.ncbi.nlm.nih.gov/articles/PMC6354384/
Plasma anandamide concentrations are lower in children with autism spectrum disorder
https://pmc.ncbi.nlm.nih.gov/articles/PMC5848550/
Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder
https://pmc.ncbi.nlm.nih.gov/articles/PMC11332686/

09/04/2026

Cannabis and acute stress disorder belong in a serious research conversation because acute stress isn’t just someone “feeling overwhelmed.” Acute stress can hit the nervous system like a storm, bringing fear, panic, sleep disruption, intrusive thoughts, hypervigilance, rapid heart rate, muscle tension, gut changes, anger, sadness, and a body that can’t find the off switch after trauma or extreme pressure.

The ECS sits at the center of that response because it helps regulate fear, stress adaptation, memory processing, emotional tone, inflammation, sleep, and how the brain decides whether danger is still present. When the ECS is supported, the nervous system may have a better chance of returning to balance instead of staying locked in fight-or-flight.

THC and C*D have both been examined in stress and anxiety research, and the picture keeps showing that dose, ratio, timing, s*x differences, and the person’s own biology matter.

Some studies suggest females may respond differently to cannabinoids during acute stress, and one study found female cannabis users showed a flatter alpha-amylase stress response compared with male cannabis users and non-users during an acute psychosocial stress test.

That doesn’t mean cannabis works better for every female, but it does show biological s*x can shape how the stress system responds to cannabis.

C*D-dominant cannabis has also shown promise in anxiety-related research. A quasi-experimental study found C*D-dominant cannabis use was associated with acute tension reduction and longer-term reductions in anxiety symptoms. At the same time, THC-dominant products did not perform the same way on some anxiety measures.

CBG is now stepping into the scene too, with a double-masked, placebo-controlled crossover trial finding that 20 mg h**p-derived CBG reduced subjective anxiety and stress in healthy cannabis-using adults without intoxication, motor impairment, or cognitive impairment.

That’s why I don’t look at acute stress through THC alone. THC may help some people relax, C*D may stabilize the stress terrain, and CBG may offer another non-intoxicating tool for anxiety and stress modulation. Add CBGa, C*Da, PEA, OEA, terpenes, sleep, breathwork, movement, hydration, nutrition, and safe support, and now we’re talking about ECS Balance instead of just chasing relief.

The plant can help calm the storm, but the goal is teaching the nervous system how to find peace again.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

S*x differences in neuroendocrine, sympathetic nervous system, and affect responses to acute stress in cannabis users
https://pubmed.ncbi.nlm.nih.gov/37367968/
Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower
https://pubmed.ncbi.nlm.nih.gov/38252547/
Acute effects of cannabigerol on anxiety, stress, and mood
https://pubmed.ncbi.nlm.nih.gov/39003387/

09/04/2026

I personally believe a lot of folks that are filled with both love and hatred right now are very balanced (love) or imbalanced (hate) within their ECS, as it controls our moods and hormone stability.

I’m seeing too much testosterone coming out of people that aren’t men. Men make sure women are safe, they put themselves last in line. Those two simple definitions are all I need in 2026.

And I see a lot of estrogen flowing from women who love the world, it also comes from Men who love the world. One really odd thing that I’m finding is Low Testosterone in many that are acting online like they have an abundance.

The lesson of the day is choose what you want toread wisely, choose who you’ll listen to the same - don’t feed into the negative, don’t become part of the garbage noise most of us are trying to avoid.

09/04/2026

Sure, plant cannabinoids are great tools, and for some people they’re necessary at times, while for others they may be needed every day. I’m one of those people who respects what cannabinoids can do because I’ve lived it, but I also know the plant works best when we stop treating it like the whole protocol and start using it as part of a full-body plan.

We can rebuild our ECS with nature. We can support it with exercise, the right diet, hydration, sleep, sunlight, minerals, stress control, gut health, breath, movement, and choices that tell the body it’s safe enough to regulate again. The Endocannabinoid System is not just waiting for THC, C*D, CBGa, C*Da, CBG, CBC, CBN, or THCa to show up. It’s already producing anandamide, 2-AG, PEA, OEA, and related lipid messengers that respond to how we live.

Exercise is one of the clearest examples. A systematic review and meta-analysis found that acute exercise can increase circulating anandamide, and a 2024 review reported that aerobic exercise can raise endocannabinoids like anandamide and 2-AG, helping support mood elevation and stress regulation. That means movement isn’t just burning calories. It’s teaching the ECS to speak again.

Diet matters too because endocannabinoids are lipid-based messengers, and the fats we eat help shape the chemistry the body can make. Research on diet and the ECS shows that fatty acid composition can influence endocannabinoid tone, inflammation, energy balance, and mood, while omega-3 fatty acids have been shown to modulate endocannabinoid tone and support inflammatory and cardiometabolic balance.

This is why I don’t teach plant cannabinoids without lifestyle. Cannabinoids can help guide the system, but the body still needs the raw materials and daily signals to rebuild itself. If we keep feeding stress, poor sleep, bad food, dehydration, and inactivity, the ECS has to fight uphill no matter what we take.

The plant is powerful, but nature gave us more than the plant. It gave us movement, food, sunlight, breath, water, rest, and the ability to heal when we finally support the system that regulates it all.

ECS Balance is not just something we take.

It’s something we live.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System
https://pubmed.ncbi.nlm.nih.gov/34870469/

Endocannabinoid system and cardiometabolic risk factors: omega-3 fatty acids
https://pubmed.ncbi.nlm.nih.gov/32184122/

Diet, endocannabinoids, and health
https://pubmed.ncbi.nlm.nih.gov/31280882/

09/04/2026

Chronic pancreatitis can become a brutal pain condition because the pancreas doesn’t suffer quietly. When inflammation keeps returning or never fully calms down, it can sensitize the nerves that carry pain signals from the pancreas into the spinal cord and brain. That’s when pain stops acting like a simple warning signal and starts becoming a chronic neurological loop.

One major player in that loop is TRPV1, a heat- and pain-sensing channel found on dorsal root ganglion neurons, also known as DRG neurons. These sensory nerve cells carry pain information from the body to the central nervous system.

In chronic pancreatitis, TRPV1 can become upregulated and sensitized, which means the same inflammatory trigger can create a louder pain response than it should. Research shows TRPV1 expression increases in DRG neurons and pancreas-specific sensory neurons in chronic pancreatitis models, making it a key target for pancreatic pain research.

This is where the ECS belongs in the conversation because endocannabinoid signaling and TRP channels often share the same pain and inflammation terrain. The ECS helps modulate pain, immune activity, gut function, inflammation, and nervous system sensitivity, while cannabinoids may influence pain pathways connected to CB1, CB2, TRPV1, TRPA1, cytokines, and neurogenic inflammation.

A pancreatitis study found cannabinoids reduced pain-related behavior and partially reduced inflammation and disease pathology in a cerulein-induced model. In contrast, another study found serum endocannabinoid levels may be associated with pancreatitis stage and pancreatitis-related pain.

That doesn’t mean cannabinoids cure chronic pancreatitis or replace medical care, enzyme support, nutrition, imaging, pain specialists, or emergency care when needed. It means the ECS is part of the pain map, and when inflammation keeps sensitizing nerves, cannabinoid science deserves a seat at the table.

Chronic pancreatitis pain isn’t just in the pancreas. It’s inflammation, nerves, receptors, and the brain learning pain too well.

The goal is to calm the fire before the signal becomes the disease.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

Transient receptor potential vanilloid 1 mediates hyperalgesia and is upregulated in rats with chronic pancreatitis
https://pubmed.ncbi.nlm.nih.gov/17698068/
Cannabinoids Ameliorate Pain and Reduce Disease Pathology in Cerulein-Induced Acute Pancreatitis
https://pmc.ncbi.nlm.nih.gov/articles/PMC2268094/
Association of Serum Endocannabinoid Levels with Pancreatitis and Pancreatitis-Related Pain
https://pubmed.ncbi.nlm.nih.gov/39291350/

09/03/2026

Our body needs balance across all systems because homeostasis isn’t a wellness slogan; it’s survival.

The Endocannabinoid System is one of the body’s great conductors, helping tune the symphony of endocannabinoids, receptors, enzymes, nerves, immune cells, hormones, and metabolic signals that keep equilibrium moving through the body.

People toss around the word “balance” like it’s soft language, but real biological balance is what lets us sleep, digest, repair, move, think clearly, calm pain, regulate mood, cool inflammation, and recover from stress.

The ECS helps modulate pain, appetite, nausea, gut motility, immune response, inflammation, stress chemistry, emotional tone, and the way the nervous system decides whether to keep firing or finally calm down.

Research on the gut-brain axis describes the ECS as a major signaling system involved in gastrointestinal function, stress response, inflammation, motility, and visceral pain.

Here’s the part many people miss - we influence this system every day. How we eat, sleep, breathe, move, feel, medicate, hydrate, and handle stress all impacts ECS tone and receptor function.

If we flood the system with too much THC without supporting cannabinoids like C*D, CBGa, C*Da, CBG, CBC, CBN, THCa, PEA, OEA, and our own endocannabinoids, the rhythm can swing out of sync. That’s not just a strain problem. It can become an ECS problem.

The ECS doesn’t act alone, but it speaks to nearly every major system we care about. When it’s disrupted, digestion can change, pain can get louder, immunity can shift, hormones can feel off, sleep can break apart, and mental clarity can fade.

That’s why homeostasis is the real goal, because relief, wellness, recovery, and resilience all start with getting the ECS tuned.

Balance is internal. We can seek help externally, but we can’t outsource the whole job to a pill, a tincture, or a product. The plant provides tools, the body provides intelligence, and we have to use both wisely.

The greatest healer isn’t a pill - it’s your body in balance.

Mike Robinson
Founder, Global Cannabinoid Research Center
The Researcher OG

The Role of the Endocannabinoid System in the Brain-Gut Axis
https://pmc.ncbi.nlm.nih.gov/articles/PMC4961581/
The Endocannabinoid System: A Potential Therapeutic Target for Co-Morbid Pain and Metabolic Dysfunction
https://pmc.ncbi.nlm.nih.gov/articles/PMC6912691/

The Researcher OG

09/06/2026

09/06/2026

09/05/2026

09/05/2026

09/05/2026

09/04/2026

09/04/2026

09/04/2026

09/04/2026

09/03/2026

Address

Opening Hours

Website

Alerts

Shortcuts

Featured

Share

Category

Listing takedown request

Monday	10am - 6pm
Tuesday	7am - 5pm
Wednesday	7am - 5pm
Thursday	2pm - 10pm
Friday	2pm - 10pm
Saturday	10am - 5pm
Sunday	6pm - 10pm